Overview
Maher Masri-El practices practicing medicine in Toronto, Canada.
His clinical expertise encompasses Triple-Negative Breast Cancer, Methicillin-Resistant Staphylococcus Aureus (MRSA), and Pneumonia.
He is actively involved in clinical research, co-authoring 70 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Maher M. Masri-El
Is Maher M. Masri-El a top-rated expert for Triple-Negative Breast Cancer?
MediFind is an objective health platform that identifies experts based on real-world data. Maher M. Masri-El is classified as an Experienced expert for Triple-Negative Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Maher M. Masri-El participate in research or clinical trials?
Yes. Maher M. Masri-El has published 70 articles and abstracts on conditions like Triple-Negative Breast Cancer. You can view a list of Maher M. Masri-El's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Methicillin-Resistant Staphylococcus Aureus (MRSA)
- PneumoniaMr. Masri-El isExperienced. Learn about Pneumonia.
- Triple-Negative Breast CancerMr. Masri-El isExperienced. Learn about Triple-Negative Breast Cancer.